Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas. Current standard treatment for GBM involves a combination of cytoreduction through surgical resection, followed by radiation with concomitant and adjuvant chemotherapy (temozolomide). The role of bevacizumab in the treatment of GBM continues to be a topic of ongoing research and debate. Despite aggressive treatment, these tumors remain undoubtedly fatal, especially in the elderly. Furthermore, tumors present in the pineal gland are extremely rare, accounting for only 0.1-0.4 % of all adult brain tumors, with this location adding to the complexity of treatment. We present a case of GBM, at the rare location of pineal gland, in an elderly patient who was refractory to initial standard of care treatment with radiation and concomitant and adjuvant temozolomide, but who developed a significant response to anti-angiogenic therapy using bevacizumab.
Myeloid sarcoma (MS) is a rare malignant condition that is defined by an extramedullary collection of immature myeloid cells and occurs in 3% of acute myeloid leukemia (AML). The presence of isolated MS is synonymous for AML. Usual locations of MS include the skin, lymph nodes, and gastrointestinal tract (1). Although up to 16% of MS cases occur in the head and neck, reports of temporal bone MS are rare (2,3). The clinical presentation of MS typically occurs secondary to mass effect in these regions with nonspecific symptoms (2,4).There is no established treatment protocol; however, early and aggressive induction chemotherapy followed by radiation offers the best chances of survival (5). Longterm prognosis remains dismal; therefore, prompt recognition of MS is critical. Herein, we present a rare head and neck presentation of relapsing AML presenting as temporal bone MS. CASEA 38-year-old man with a history of CKIT negative, AML with inv(16) had previously undergone 7 + 3 induction chemotherapy (fludarabine, cytarabine, idarubicin, and filgrastim), 4 cycles of consolidation, and a matched donor transplant. Ten months after bone marrow transplant, the patient was in morphologic remission. He presented to the emergency room 2 months later with a 3-week history of intermittent otalgia, sudden onset left-sided facial paralysis, and severe retroauricular pain. Physical examination revealed left-sided facial nerve palsy, HouseBrackmann 3/6, a left middle ear effusion, and tender left-side lymphadenopathy. The remainder of the examination was unremarkable with no other neurologic or rightsided symptoms.Subsequent CAT scan (CT) imaging revealed opacification of the mastoid antrum and mastoid air cells on the left, with a soft tissue mass with intracranial and extracranial components (Fig. 1). Magnetic resonance imaging was also obtained, which confirmed the CT findings with suggestion of extension of the lesion through the sigmoid plate into the mastoid (Fig. 2).The initial differential diagnosis included acute mastoiditis versus leukemic infiltration. Left-sided myringotomy with PE tube placement was placed upon presentation, and he was started on ofloxacin drops and 10 mg of dexamethasone IV. The results of the imaging prompted a CT-guided The authors disclose no conflicts of interest. FIG. 1. A, Axial CT soft tissue window reveals an approximately 3.2 cm AP Â 3.8 cm transverse lesion with an intracranial component approximately 2.0 cm AP Â 1.7 cm transverse. The extracranial component is within the retroauricular soft tissues and measures 8 mm in transverse and 2.6 cm in anteroposterior dimensions. This lesion was slightly hyperdense and blended with the sigmoid sinus. B, Axial CT bone window demonstrates permeation of the left sigmoid plate within the sigmoid groove and permeative destruction of the outer wall of the mastoid.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.